Great news! On 15 April 2026, Vonoprazan Fumarate Tablets (10mg/20mg) of Sichuan Difeite Pharmaceutical co., Ltd., a subsidiary of Xieli Group, has been officially approved for marketing. This approval represents a significant new addition to the Group’s portfolio in the chronic disease segment, and marks an important milestone in the implementation of our “API + Formulation” integrated strategy.

The successful approval marks a key step forward for the Group in building a complete API + Formulation industrial chain and establishing core competitive advantages. It injects strong impetus into further expanding the digestive chronic disease market and deeply cultivating the chronic disease treatment sector.

Moving forward, the Group will stay committed to its integrated strategy, focusing on innovative R&D in digestive chronic diseases and optimizing its full industrial chain layout, and support the high-quality development of the chronic disease field with high-quality products.